Metabiomics Colon Cancer Clinical Research Study

Metabiomics

Status: Withdrawn

Conditions: Colonic Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT02151123

MB-02_CU

Details and patient eligibility

About

The specific aim of the study is to determine the false negative rate of the Metabiomics Colon Polyp and Colorectal Cancer Assay for Cancer.

Full description

The purpose of this study is to conduct clinical research to investigate the association of the gut microbiome with colonic neoplasia. In this case several types of gut microbiome samples will be collected from patients undergoing colectomy for colonic adenocarcinoma; those samples will be tested by Metabiomics Colon Polyp and Colorectal Cancer Assay and the percentage of false negative (test returns a negative for cancer) results determined.

Sex: All

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recently diagnosed with colorectal cancer (CRC) and scheduled for colectomy
• Male or female,
• Age: 18-95 years,
• Able to comprehend, sign, and date the written informed consent form (ICF),
• Able to give informed consent in English
• Women and minorities will be included.

Exclusion criteria

• History of Inflammatory Bowel Disease
• Antibiotics within 2 weeks of sample collection.
• Colonoscopy, colon prep or bowel contrast agent within 7 days prior to sample collection
• Any radiation therapy

Trial design

0 participants in 1 patient group

Diagnosed colon cancer patients

Description:

Patients undergoing colectomy for colonic adenocarcinoma.